Samsung chief visits biotech drug arm

Samsung Electronics Executive Chairman Lee Jae-yong, right, receives a briefing at the construction site of Plant 5, which Samsung Biologics is building in Songdo, Incheon, Friday. The Samsung Group leader inspected the construction site of Plant 5, which will be completed in 2025, and Plant 4, which is currently in operation. Courtesy of Samsung Electronics
Samsung Electronics Chairman Lee Jae-yong on Friday visited Samsung Biologics, a biotech drug unit of Samsung Group, marking his first local schedule since he was acquitted in connection with the controversial 2015 merger of two affiliates.
Earlier this month, a court delivered the not-guilty sentence for Lee, three years and five months after he was indicted on charges of involvement in market irregularities in the merger of Cheil Industries Inc. and Samsung C&T.
Lee made a visit to Biologics in Incheon, west of Seoul, where its fifth production facility is being built, and held a meeting with its executives, encouraging them to set a higher business goal, the company said in a statement.
Last year, Biologics posted sales of 3.7 trillion won ($2.7 billion) with an operating profit of 1.1 trillion won. (Yonhap)